ImmuPharma plc (AIM: IMM) has filed an international Patent Cooperation Treaty application covering its P140 precision medicine approach to autoimmune disease, including identifying and treating patients with the Type M immune profile.
The filing builds on the company’s original UK priority application from August 2025 and represents the next stage in seeking international protection for intellectual property generated around P140 and Type M.
During the 12-month priority period, ImmuPharma generated additional experimental data supporting the scientific basis of the approach, which has now been incorporated into the international application.
The PCT process will move through international search and publication before ImmuPharma selects the key national and regional markets in which it intends to pursue patent protection.
P140 remains a core strategic asset for the company, which said partnering discussions are continuing and that it remains focused on completing a value-enhancing commercial deal during 2026.
Dr Sébastien Goudreau, Chief Scientific Officer of ImmuPharma PLC, said: “The filing of the PCT application represents an important next step in protecting the intellectual property generated through our work on P140 and Type M. During the priority period, we continued to generate additional experimental data, which have now been incorporated into PCT application and further support the scientific rationale underlying our precision medicine approach. The PCT filing enables us to progress our international patent strategy alongside the broader development of P140.”
Tim McCarthy, Chief Executive Officer of ImmuPharma PLC, added: “With the PCT filing now completed and additional supporting data incorporated into the application, P140 continues to progress as a key strategic asset for ImmuPharma. Our focus remains on advancing discussions and completing a value-enhancing commercial deal in 2026.”
ImmuPharma will provide further updates on the P140 program as appropriate.
